Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

1) receptor blockade -- in one molecule to treat high blood pressure.

"We are very pleased with the results of this important Phase 2a trial and look forward to future studies which will further assess the potential of PS433540, perhaps even beyond blood pressure lowering," said Joseph A. Mollica, Ph.D., Chairman of the Board and Interim President and Chief Executive Officer of Pharmacopeia. "We believe PS433540's dual mechanism of action may have a positive effect on diabetic kidney disease."

Patients with diabetes are at an increased risk for many complications, including high blood pressure and diabetic kidney disease. Up to 73 percent of patients with diabetes have been or are being treated for high blood pressure,(5) and an estimated 20-30 percent of diabetic patients will progress to diabetic kidney disease,(6) a devastating disease that may require patients to undergo dialysis or a kidney transplant.(7)

Pharmacopeia recently initiated a 12-week, Phase 2b clinical trial with PS433540 to evaluate the compound's safety and efficacy at three different doses versus placebo in 375 subjects with Stage I and Stage II hypertension. The study will also compare blood pressure reductions for each dose with irbesartan. Pharmacopeia anticipates completion of the Phase 2b trial at the end of 2008.

About the Phase 2a study

In this prospective study, 234 men and women with Stage I and Stage II hypertension entered into a single blind placebo run-in period for 3-4 weeks, after which 114 were randomized to receive double blind study medication for four weeks. At the time of the database lock, 108 subjects were available for evaluation, 93 of whom had both baseline and follow-up ambulatory blood pressure measurements (placebo: 25; PS433540 200mg: 35; PS433540 500mg: 33). The primary endpoint was the subjects' change from baseline in mean 24-hour systolic ambulatory blood pressure after 4 weeks of treatment. Additionally, investigators evaluated
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Today Eli Lilly and Company (NYSE: LLY ... to increase the global supply of medicines for multidrug-resistant ... donating manufacturing technology and know-how for two antibiotics to ... India , Russia ... MDR-TB ,hot spots., It also served as the foundation ...
(Date:10/27/2014)... Research and Markets has announced the addition of ... their offering. H1N1 influenza (zoonotic) is an ... swine H1N1 virus, known as H1N1v virus. The H1N1v virus ... H1N1 virus is an RNA virus belonging to the Orthomyxoviridae ... humans, swine, birds, seals, and horses. Influenza A viruses can ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... , LAKE FOREST, Ill. , Jan. 12 ... of injectable pharmaceuticals announced today the launch of Ibutilide ... from Pfizer Inc. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , ... Pharma,s continued growth and dedication to a consistently expanding ...
... Jan. 12 CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of approximately 15%, to 8.75 cents per share on ... holders of record on January 22, 2010 . This increase translates into ... cents per share from the previous rate of 30.5 cents . ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2CVS Caremark Corporation Increases Quarterly Dividend 15% 2
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, plans ... that you are never too young to give back ... and Carl at the 2013 Santa Arriving By Helicopter ... Chamber of Commerce. Tracey gave Timothy a special tour ... his real fireman’s hat, and extending an offer to ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... Commission Accredited teleradiology and specialty telemedicine solutions provider, ... addition to its existing teleradiology services at Mission ... opinion and expert telemedicine services, to the state-of-the-art, ... As a result of this innovative partnership, there ...
(Date:10/30/2014)... Sound Telecom, a leader in the call ... people any time they wonder, “Should I use an answering ... leading them through a series of yes or no questions ... , There are many considerations and scenarios that come into ... answering service . This decision infographic serves as a bit ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... ... to Walk with Style , ... Portland, OR (PRWEB) March 31, 2010 -- Pat Heyward Canes, a new provider of fashion ... designer patterns for men and women ranging from classic to whimsical. Made from performance ...
... ... efforts , ... Lake City, UT (Vocus) March 31, 2010 -- Venafi, Inc. ( www.venafi.com ) today ... when encryption keys are not properly monitored and managed., , ,Visit this link to ...
... ... for its innovative work in bringing about positive, scalable community-led change in thousands of ... ... named nonprofit Tostan as a 2010 recipient of its prestigious Skoll ...
... believed to bear fruit that ripened into a living baby ... as new treatments for osteoporosis, the bone-thinning disease. That,s the ... of Natural Products . Young Ho Kim and ... affecting up to 6 million women and 2 million men ...
... popular imaging procedures such as virtual colonoscopy , WEDNESDAY, ... imaging technologies are exposing Americans to too much radiation ... U.S. Food and Drug Administration concludes two days of ... increase the safety of these procedures. , Specifically, the ...
... ... Deliver Critical Support for Users of Chemicals , ... Vancouver, WA and Tampa, FL (PRWEB) March 31, 2010 ... ChemTel, Inc., the nation’s premiere emergency response support center, are pleased to announce a ...
Cached Medicine News:Health News:Pat Heyward Canes Unveils New Stylish Walking Cane Collection Just in Time for Mother's Day 2Health News:PCI Compliance and Data Security Requires Private Key Management – New Industry White Paper Explains 2Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 2Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 3Health News:Tostan and Molly Melching Receive 2010 Skoll Award for Social Entrepreneurship 4Health News:FDA Hears Views on Risks of High Tech Scanners 2Health News:FDA Hears Views on Risks of High Tech Scanners 3Health News:FDA Hears Views on Risks of High Tech Scanners 4Health News:Safetec and ChemTel Announce Partnership 2Health News:Safetec and ChemTel Announce Partnership 3
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... Excilite- is a portable, compact, lightweight ... capable of emitting the same intensity (50 ... on a smaller treatment area (30 cm). ... order to satisfy the most demanding professional ...
... system used in neurophysiology for studying evoked potentials. ... and/or the duration of the stimulus as well ... emission in an ongoing manner by acting on ... include the high repeatability of the impulses, the ...
... 1.0 is a high power pulsed ... response to pain, even in the ... differs from the other laser devices ... full safety, all the 3 laser ...
Medicine Products: